Maritoclax
CAS: 1227962-62-0
Ref. 3D-CZB96262
| 5mg | A consultar | |
| 10mg | A consultar | |
| 25mg | A consultar | |
| 50mg | A consultar | |
| 100mg | A consultar |
Información del producto
- 1,1'-(4,4',5,5'-Tetrachloro[1,3'-bi-1H-pyrrole]-2,2'-diyl)bis[1-(2-hydroxyphenyl)methanone]
Maritoclax is a low-potency, selective inhibitor of the mcl-1 protein. It has been shown to increase the sensitivity of leukemia cells to chemotherapy by inducing apoptosis in leukemia cells that express wild-type mcl-1 and chemoresistance in those that have mutated the protein. Maritoclax has also been shown to be effective against skin cancer in vivo, where it inhibits proliferation and induces apoptosis. In addition, maritoclax can induce apoptosis in primary cells from human patients with autoimmune diseases such as systemic lupus erythematosus.
Mutations in cyclin D2 may lead to resistance to maritoclax treatment because the drug only works on cells with wild-type cyclin D2 expression. This drug may also be synergistic with other drugs that target cell proliferation, such as gemcitabine or cetuximab.
Propiedades químicas
Consulta técnica sobre: 3D-CZB96262 Maritoclax
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
